|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most of the early studies were performed with PET and [ <sup>18</sup> F]fluorodeoxyglucose, and occasionally with [ <sup>15</sup> O]water, reporting a significant association between higher occupation/education and lower glucose metabolism (blood flow) in associative temporo-parietal cortex in patients with AD and also in patients with MCI, after correcting for the degree in the cognitive impairment.
|
30784080 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals aged 55-75 years who live in the United States and self-report not having a diagnosis of cognitive impairment such as MCI or dementia are eligible to join GeneMatch.
|
30772251 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Early prevention of MCI-related risk factors provides effective means to retard cognitive decline in PD patients.
|
30732989 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MINT successfully detects naming deficits at different levels of cognitive impairment in patients with MCI or AD dementia, but comparison to age, sex, race, and education-corrected norms to determine impairment is essential.
|
31248465 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 96 SNPs across five genes (APOE/TOMM40, BDNF, COMT, SORL1, and KIBRA) in 2857 women (ages ≥65) from the WHIMS randomized trials of hormone therapy using a custom Illumina GoldenGate assay; 19% of the sample were MCI (N = 165) or PD (N = 387), and the remaining 81% were free of cognitive impairment.
|
30706571 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extending the discriminative validity analysis to cognitive impairment (both dementia and MCI, n = 162) only slightly reduced the discriminative validity of BASIC whereas the discriminative validity of the MMSE was substantially attenuated.
|
31389089 |
2019 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further high-quality evidence is needed in order to determine whether mind-body interventions are cost-effective for improving cognitive decline in older adults with MCI and for delaying the rapid progression from MCI to Alzheimer or other types of dementia.
|
30712518 |
2019 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
To better answer this point, we quantified cortical perfusion with arterial spin labeling (PVC-CBF), measured ultrasound internal carotid (ICA), and femoral (FA) artery blood flow in a group of patients with similar age (~78 years) but different cognitive impairment (i.e., mild cognitive impairment MCI, mild AD-AD1, moderate AD-AD2, and severe AD-AD3) and compared them to young and healthy old (aged-matched) controls.
|
29593548 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
As circadian disruption is apparent in both MCI and Alzheimer's disease, and plays a key role in cognitive function, our findings further support a circadian intervention as a potential therapeutic tool for cognitive decline.
|
30320584 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
The optimal cutoff point is 42/43 for identifying cognitive impairment (MCI-A and AD dementia) against CN (sensitivity 97.80% and specificity 89.13%) and MCI-A against CN (sensitivity 86.60% and specificity 94.20%).
|
29376851 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report results from a single-case study in which DFMO was administered, for the first time, in an attempt to slow progression of AD in a single woman with multi-domain, amnestic MCI who was unable to tolerate an acetylcholinesterase inhibitor.<b>Methods:</b> Patient C.S. is a 74-year old female with a 5-year history of cognitive decline who was placed on DFMO (500 mg b.i.d.) for 12 months, with amyloid PET scans (baseline and 12-months), APOE genotyping and neuropsychological exams at baseline, 3, 9, and 12 months.<b>Results:</b> C.S. suffered continued cognitive decline over 12 months, including progressive worsening of orientation, social functions and ability to engage in IADL's.
|
29559907 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specific attention to executive functions (EFs) has been given.A total of 144 subjects complaining of different cognitive deficits - ranging from "MCI likely due to AD" to "mild AD patients" - underwent an overall neuropsychological assessment.
|
29789032 |
2018 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Methods:</b> We included 2,934 patients (age 67 ± 9 years; 1,391 [47%] female; MMSE 24 ± 5) from the Amsterdam Dementia Cohort (1,347 dementia due to Alzheimer's disease [AD]; 681 mild cognitive impairment [MCI]; 906 controls with subjective cognitive decline).
|
28536518 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF and plasma concentrations of MIF as well as biomarkers of amyloid, neuronal injury, and tau hyperphosphorylation (CSF Aβ1-42, tau, and ptau, respectively) were assessed in 97 subjects with MCI or mild dementia (cognitive impairment, CI) and 52 healthy volunteers with normal cognition.
|
28826184 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a follow-up analysis using an independent data set, we demonstrate a protective effect of this variant against risk of conversion to MCI or AD (p = 0.038) and against cognitive decline in individuals who develop dementia (p = 3.41 × 10<sup>-15</sup> ).
|
29130521 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is unknown whether obesity or related health conditions modify the risk of NPS or severity of cognitive impairment in MCI.
|
28611655 |
2017 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred and seven elderly subjects with cognitive impairment (91 memory clinic patients with mild cognitive impairment [MCI] and 16 with dementia of AD type) and 55 cognitively healthy volunteers were included in this study.
|
29054536 |
2017 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed the clinical sensitivity of static and dynamic functional brain disruptions across the AD spectrum using resting-state fMRI in a sample consisting of AD patients (n = 80) and subjects with either mild (n = 44) or subjective (n = 26) cognitive impairment (MCI, SCI).
|
28074926 |
2017 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an exploratory analysis, 3/83 proteins (SGOT, MCP-1, IL6r) were also found to be mildly associated with cognitive decline in MCI subjects over a 4-year period.
|
26284520 |
2015 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
DLB subjects have higher amyloid burden than subjects with PDD, PD-MCI, PD, or HCS; amyloid deposits are linked to cognitive impairment only in DLB.
|
22693110 |
2012 |
|
Impaired cognition
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments.
|
22076544 |
2011 |
|
Impaired cognition
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
96 patients (33 with subjective cognitive impairment--SCI; 36 with mild cognitive impairment--MCI; 27 with AD) referred to the Memory Clinic at Karolinska University Hospital, Sweden.
|
19560513 |
2009 |